Citations

Clear

7552 citation(s) found for "Ho, Matthew".

INCREASED INCIDENCE OF CUTANEOUS KERATINOCYTIC AND MELANOCYTIC MALIGNANCIES IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
Shah, Saumya M. , Starr, Matthew R. , Comfere, Nneka I. , AbouChehade, Jackson E., Hodge, David O. , Iezzi, Raymond , Bakri, Sophie J. , Starr, Matthew R , Dalvin, Lauren A.

Mayo Clinic

Retina | April 6, 2019 | Volume: 40 | Issue: 5 | Pages: 857-865

10.1097/iae.0000000000002506 | PMID 30986797 Get It

Purpose: The relationship between age-related macular degeneration (AMD) and malignancy, especially cutaneous malignancies, is not well studied. We investigated a possible association between AMD and cutaneous malignancies. Methods: A retrospective, consecutive review of all patients who had received at least 1 intravitreal injection for wet AMD between January 1, 2004, and December 31, 2013, was conducted using the Rochester Epidemiology Project in Olmsted County, Minnesota. Age- and sex-matched control groups included 473 pre–anti–vascular endothelial growth factor era wet AMD patients, 504 concurrent time dry AMD patients, and 504 patients with no AMD. The rates of AMD and overall malignancy, cutaneous malignancies, and specific types of cutaneous malignancies were compared between groups of patients. Results: Patients with wet AMD incurred an increased rate of overall malignancies compared to patients with dry AMD {52.8% wet AMD (confidence interval [CI]: 48.3–57.2) vs. 43.7% dry AMD (CI: 39.3–48.1); P= 0.003} or those without AMD (52.8% wet AMD [CI: 48.3–57.2] vs. 35.3% no AMD [CI: 31.1–39.7]; P = <0.001). Patients with dry AMD also had higher rates of malignancy than those without AMD (43.7% dry AMD [CI: 39.3–48.1] vs. 35.3% no AMD [CI: 31.1–39.7]; P = 0.007). Rate of cutaneous malignancies was increased in patients with wet AMD compared to patients with dry AMD (24.4% wet AMD [CI: 20.7–28.4] vs. 14.6% dry AMD [CI: 11.5–17.9]; P = <0.001) and those with no AMD (24.4% wet AMD [CI: 20.7–28.4] vs. 9.7% no AMD [CI: 7.3–12.7]; P = <0.001). Conclusion and Relevance: To the best of our knowledge, this is the first report to establish an association between AMD and cutaneous malignancies, supporting a possible discussion of the association when a patient presents with one of the two conditions.
Drugs for the treatment of metabolic bone diseases
Drake, Matthew T. , Cremers, Serge , Russell, R.G.G. , Bilezikian, John P. , Russell, R Graham , Drake, Matthew T

Mayo Clinic

British Journal of Clinical Pharmacology | April 5, 2019 | Volume: 85 | Issue: 6 | Pages: 1049-1051

10.1111/bcp.13857 | PMID 30950086 Get It

Long-Term Outcomes of Constrained Liners Cemented into Retained, Well-Fixed Acetabular Components
Brown, Timothy S. , Tibbo, Meagan E. , Arsoy, Diren , Lewallen, David G. , Hanssen, Arlen D. , Trousdale, Robert T. , Abdel, Matthew P. , Abdel, Matthew P

Mayo Clinic

Journal of Bone and Joint Surgery | April 5, 2019 | Volume: 101 | Issue: 7 | Pages: 620-627

10.2106/jbjs.18.00607 | PMID 30946196 Get It

Background: Cementation of a constrained liner is a viable option for treating instability after total hip arthroplasty (THA) when the acetabular component is well fixed and well aligned. However, concerns regarding long-term mechanical failure and recurrent instability remain. The aim of this study was to evaluate the long-term survivorship, complications, and clinical and radiographic outcomes of constrained polyethylene liners cemented into well-fixed acetabular components at the time of revision THA. Methods: We identified 125 cases in which a constrained liner of 1 design was cemented into a retained, osseointegrated acetabular component during revision THA between 1998 and 2006. The mean patient age at revision was 70 years. Mean follow-up was 7 years. Survivorship data, risk of instability, and clinical and radiographic outcomes were analyzed. Results: Survivorship free from revision for instability was 86% at 5 years and 81% at 10 years. Survivorship free from aseptic acetabular component revision was 78% at 5 years and 65% at 10 years, with the most common failure mechanism being dissociation of the constrained liner from the acetabular component. Survivorship free from revision for any reason was 76% at 5 years and 60% at 10 years. The most common complications were instability and periprosthetic joint infection, with cumulative incidences at 7 years of 18% and 11%, respectively. Harris hip scores did not significantly improve. Cup position did not affect implant survivorship or risk of dislocation. Conclusions: Cementing a constrained liner into a retained acetabular shell at the time of revision THA has durable long-term results, with 8 in 10 patients free from instability at 10 years. Aseptic acetabular survivorship was worse (65%) at 10 years, primarily due to dissociation of the constrained liner from the acetabular component. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Isolated cilioretinal artery occlusion secondary to perinuclear antineutrophil cytoplasmic antibody vasculitis
Mammo, Danny A. , Chen, John , Adams, Matthew K., Pulido, José S. , Davies, John B. , Chen, John J. , Pulido, Jose, Chen, John J , McClelland, Collin M. , Davies, John B

Mayo Clinic

European Journal of Ophthalmology | April 5, 2019 | Volume: 30 | Issue: 5 | Pages: NP53-NP57

10.1177/1120672119841541 | PMID 30947529 Get It

Introduction: Antineutrophil cytoplasm antibody-associated vasculitides encompass a diverse spectrum of autoimmune diseases characterized by necrotizing small vessel vasculitis. Ocular manifestations may be the presenting findings of antineutrophil cytoplasm antibody-associated vasculitides. Methods: Single, retrospective case study. Results: We report the rare case of a 55-year-old woman with a cilioretinal artery occlusion as the presenting feature of perinuclear antineutrophil cytoplasm antibody-associated microscopic polyangiitis. Conclusions: Although rare, antineutrophil cytoplasm antibody-related vasculitis should be considered in any retinal vascular occlusion, particularly in the setting of patients with new vague headaches and a paucity of vasculopathic risk factors.
An Introduction to RA21: Taking Authentication Beyond IP Addresses
Hoy, Matthew B.

Mayo Clinic

Medical Reference Services Quarterly | April 3, 2019 | Volume: 38 | Issue: 1 | Pages: 81-86

10.1080/02763869.2019.1554370 | PMID 30942682 Get It

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Evgin, Laura , Kottke, Timothy, Thompson, Jill , Molan, Amy M. , Driscoll, Christopher B. , Schuelke, Matthew , Shim, Kevin G. , Wongthida, Phonphimon , Ilett, Elizabeth J. , Smith, Karen Kaluza, Pulido, José S. , Pandha, Hardev , Selby, Peter J. , Harrington, Kevin J. , Melcher, Alan , Vile, Richard G. , Huff, Amanda L. , Shim, Kevin G , Ilett, Elizabeth J , Melcher, Alan A , Harrington, Kevin , Driscoll, Christopher , Harris, Reuben S. , Coffey, Matt C.

Mayo Clinic

Cancer Immunology Research | April 2, 2019 | Volume: 7 | Issue: 5 | Pages: 828-840

10.1158/2326-6066.cir-18-0013 | PMID 30940643 Get It

Abstract Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). We show here that T cells that recognize tumor-associated antigens can directly kill tumor cells if used at high effector-to-target ratios. However, when these tumor-reactive T cells were present at suboptimal ratios, direct T-cell–mediated tumor cell killing was reduced and the ability of tumor cells to evolve away from a coapplied therapy (oncolytic or suicide gene therapy) was promoted. This T-cell–mediated increase in therapeutic resistance was associated with C to T transition mutations that are characteristic of APOBEC3 cytosine deaminase activity and was induced through a TNFα and protein kinase C–dependent pathway. Short hairpin RNA inhibition of endogenous APOBEC3 reduced rates of tumor escape from oncolytic virus or suicide gene therapy to those seen in the absence of antitumor T-cell coculture. Conversely, overexpression of human APOBEC3B in tumor cells enhanced escape from suicide gene therapy and oncolytic virus therapy both in vitro and in vivo. Our data suggest that weak affinity or low frequency T-cell responses against tumor antigens may contribute to the ability of tumor cells to evolve away from first-line therapies. We conclude that immunotherapies need to be optimized as early as possible so that, if they do not kill the tumor completely, they do not promote treatment resistance.
The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?
Miller, Virginia M. , Naftolin, Frederick , Asthana, Sanjay , Black, Dennis M. , Budoff, Matthew J. , Cedars, Marcelle I. , Dowling, N. Maritza , Gleason, Carey E. , Hodis, Howard N., Jayachandran, Muthuvel , Kantarci, Kejal , Løbo, Rogerio A. , Pal, Lubna , Taylor, Hugh S. , Harman, S. Mitchell , Asthana, Sanjay , Kantarci, Kejal , Budoff, Matthew , Brinton, Eliot A. , Manson, JoAnn E. , Santoro, Nanette F.

Mayo Clinic

Menopause | April 2, 2019 | Volume: 26 | Issue: 9 | Pages: 1071-1084

10.1097/gme.0000000000001326 | PMID 31453973 Get It

Abstract Objective: The Kronos Early Estrogen Prevention Study (KEEPS) was designed to address gaps in understanding the effects of timely menopausal hormone treatments (HT) on cardiovascular health and other effects of menopause after the premature termination of the Women's Health Initiative. Method: The KEEPS was a randomized, double-blinded, placebo-controlled trial to test the hypothesis that initiation of HT (oral conjugated equine estrogens [o-CEE] or transdermal 17β-estradiol [t-E 2 ]) in healthy, recently postmenopausal women ( n = 727) would slow the progression of atherosclerosis as measured by changes in carotid artery intima-media thickness (CIMT). Results: After 4 years, neither HT affected the rate of increase in CIMT. There was a trend for reduced accumulation of coronary artery calcium with o-CEE. There were no severe adverse effects, including venous thrombosis. Several ancillary studies demonstrated a positive effect on mood with o-CEE, and reduced hot flashes, improved sleep, and maintenance of bone mineral density with both treatments. Sexual function improved with t-E 2 . There were no significant effects of either treatment on cognition, breast pain, or skin wrinkling. Variants of genes associated with estrogen metabolism influenced the age of menopause and variability in effects of the HT on CIMT. Platelet activation associated with the development of white matter hyperintensities in the brain. Conclusions: KEEPS and its ancillary studies have supported the value and safety of the use of HT in recently postmenopausal women and provide a perspective for future research to optimize HT and health of postmenopausal women. The KEEPS continuation study continues to pursue these issues.
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Bartlett, Nancy L. , Wilson, Wyndham H. , Pederson, Levi , Polley, Mei‐Yin C. , Pitcher, Brandelyn N., Cheson, Bruce D. , Friedberg, Jonathan W. , Staudt, Louis M. , Wagner‐Johnston, Nina D. , Blum, Kristie A. , Reddy, Nishitha , Chang, Julie , Chadburn, Amy , Mathew, Susan , Fisher, Richard I., Richards, Kristy L. , Leonard, John P. , Bartlett, Nancy L , Jung, Sin‐Ho , Hsi, Eric D. , Maurer, Matthew J. , Kahl, Brad S. , Abramson, Jeremy S. , Winter, Jane N. , Gopal, Ajay K. , Schöder, Heiko , Zelenetz, Andrew D.

Mayo Clinic

Journal of Clinical Oncology | April 2, 2019 | Volume: 37 | Issue: 21 | Pages: 1790-1799

10.1200/jco.18.01994 | PMID 30939090 Get It

PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma. PATIENTS AND METHODS Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall survival (OS), and safety. RESULTS Between 2005 and 2013, 524 patients were registered; 491 eligible patients were included in the final analysis. Most patients (74%) had stage III or IV disease; International Prognostic Index (IPI) risk groups included 26% IPI 0 to 1, 37% IPI 2, 25% IPI 3, and 12% IPI 4 to 5. At a median follow-up of 5 years, PFS was not statistically different between the arms (hazard ratio, 0.93; 95% CI, 0.68 to 1.27; P = .65), with a 2-year PFS rate of 78.9% (95% CI, 73.8% to 84.2%) for DA-EPOCH-R and 75.5% (95% CI, 70.2% to 81.1%) for R-CHOP. OS was not different (hazard ratio, 1.09; 95% CI, 0.75 to 1.59; P = .64), with a 2-year OS rate of 86.5% (95% CI, 82.3% to 91%) for DA-EPOCH-R and 85.7% (95% CI, 81.4% to 90.2%) for R-CHOP. Grade 3 and 4 adverse events were more common ( P < .001) in the DA-EPOCH-R arm than the R-CHOP arm, including infection (16.9% v 10.7%, respectively), febrile neutropenia (35.0% v 17.7%, respectively), mucositis (8.4% v 2.1%, respectively), and neuropathy (18.6% v 3.3%, respectively). Five treatment-related deaths (2.1%) occurred in each arm. CONCLUSION In the 50303 study population, the more intensive, infusional DA-EPOCH-R was more toxic and did not improve PFS or OS compared with R-CHOP. The more favorable results with R-CHOP compared with historical controls suggest a potential patient selection bias and may preclude generalizability of results to specific risk subgroups.
Expansile Traumatic Neuroma of the Intratemporal Facial Nerve
Feng, Yening , Patel, Neil , Burrows, Anthony M. , Lane, John I. , Carlson, Matthew L. , Raghunathan, Aditya , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Reports | April 1, 2019 | Volume: 80 | Issue: 01 | Pages: e10-e13

10.1055/s-0039-1685212 | PMID 30941279 Get It

Objectives To present a rare case of traumatic facial neuroma involving the geniculate ganglion and review relevant literature. Patient Thirty-year-old man. Intervention Microsurgical resection via combined mastoid-middle fossa approach with great auricular nerve interpositional graft. Main Outcome Measures Patient demographics and pre- and postoperative facial nerve function. Results A 30-year-old man with a reported history of prior Bell's palsy developed progressive complete (House–Brackmann VI) right facial paralysis following blunt trauma. Imaging was strongly suggestive of a geniculate ganglion hemangioma. As the patient had no spontaneous improvement in his poor facial function over the course of 9 months, he underwent resection of the facial nerve lesion with great auricular nerve graft interposition via a combined mastoid-middle fossa approach. Histopathology demonstrated disorganized fascicles, with axonal clustering reminiscent of sprouting/regeneration following trauma. No cellular proliferation or vascular malformation was present. Conclusion Traumatic facial nerve neuromas can occur following temporal bone trauma and can closely mimic primary facial nerve tumors. Akin to the management of geniculate ganglion hemangioma and schwannoma, preoperative facial function largely dictates if and when surgery should be pursued.
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Ismaila, Nofisat , Cheung, Matthew C. , Costello, Caitlin , Dhodapkar, Madhav V. , Kumar, Shaji , Lacy, Martha Q. , Lipe, Brea , Little, Richard F. , Nikonova, Anna S., Omel, James, Peswani, Namrata, Seth, Rahul , Vesole, David H. , Walker, Irwin , Whitley, Alexander C., Wildes, Tanya M. , Wong, Sandy W. , Martin, Tom, Lacy, Martha, Wildes, Tanya , Mıkhael, Joseph , Lipe, Brea , Nikonova, Anna, Prica, Anca A. , Raje, Noopur , Seth, Rahul

Mayo Clinic

Journal of Clinical Oncology | April 1, 2019 | Volume: 37 | Issue: 14 | Pages: 1228-1263

10.1200/jco.18.02096 | PMID 30932732 Get It

PURPOSE To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 124 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.